1 / 16

Herpes Simplex Virus, Type 1

Effect of antiviral use on the emergence of resistance to nucleoside analogs in Herpes Simplex Virus, Type 1 Marc Lipsitch, Bruce Levin, Rustom Antia, Jeffry Leary, Teresa Bacon. Herpes Simplex Virus, Type 1. Cause of recurrent herpes labialis (RHL =“cold sores”) More severe diseases

krysta
Download Presentation

Herpes Simplex Virus, Type 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effect of antiviral use on the emergence of resistance to nucleoside analogs in Herpes Simplex Virus, Type 1 Marc Lipsitch, Bruce Levin, Rustom Antia, Jeffry Leary, Teresa Bacon

  2. Herpes Simplex Virus, Type 1 • Cause of recurrent herpes labialis (RHL =“cold sores”) • More severe diseases • Respiratory and neurologic infections • Neonatal herpes • Disseminated disease in immunocompromised patients

  3. Impetus for work • Topical antiviral Penciclovir, available Rx in US • Sponsor wished to obtain OTC license • FDA had denied OTC Acyclovir for genital herpes • Concerns about resistance, precedent • Penciclovir sponsor requested resistance risk analysis

  4. HSV-1 Transmission • Primary asymptomatic or symptomatic infection, latency and reactivation • Infection can be detected serologically • Reactivation (cold sores) associated with heavy viral shedding • 1-5% shedding among asymptomatic carriers • Little direct evidence of when transmission occurs

  5. HSV-1 Treatment and Resistance • Nucleoside analog family • acyclovir (prodrug valacyclovir) • penciclovir (prodrug famciclovir) • Prevents viral DNA replication • Does not cure latently infected cells • Resistance readily selected in vitro and in immunocompromised patients • Resistance arises rarely in immunocompetent during treatment •  virulence (usually), transmissibility (probably)

  6. Resistance to nucleoside analogs in HSV-1 • Presently about 0.3% in immunocompetent, 3-10% in immunocompromised • No evidence of increasing trend since acyclovir was introduced in early 1980s • QUESTION: How would levels of resistance change following a substantial increase in nucleoside analog use? • Research was sponsored by the manufacturer of topical penciclovir, which wished to apply for OTC status for the treatment of RHL

  7. Basic Model for Transmission of Resistance Force of infection Asymptomatic Seropositive: Sensitive Cold Sores Untreated C.S. Treated birth Susceptible Asymptomatic Seropositive: Resistant death Force of infection Cold Sores

  8. Complex Model Immunocompetent Immunocompromised Acquired resistance IS I’S infection secondary infection birth S S’ ID I’D infection IR I’R

  9. Transmission of Resistance: Key Assumptions and Parameters • Up to 30% of cold sore sufferers use topical PCV. • Topical PCV reduces transmission of sensitive HSV-1. • Individuals infectious when symptomatic, and possibly when asymptomatic. • Resistance  transmissibility 0-50%. • PCV treatment does not cause “acquired resistance.” • Total or partial immunity to HSV-1 superinfection

  10. Acyclovir Resistance in HSV-1: Model Predictions (No acquired resistance)

  11. Acquired Resistance • Approximately 1800 immunocompetent patients with multiple viral samples in clinical trials of nucleoside analogs (HSV-1 and HSV-2, oral and topical, several different compounds). • No evidence of acquired resistance • 0/1800 95%CI (0, 0.0017)  (0, 1/625) • Biological limitations of the assay • Biological barriers • 4 possible case reports in immunocompetent

  12. Model with Acquired Resistance P(AR) = 1/2500 treated episodes P(AR) = 1/625 treated episodes No acquired resistance P(AR) = 1/6250 treated episodes

  13. Conclusions: HSV-1 • Very slow increase in prevalence of resistance from transmission alone • Acquired resistance necessary for noticeable buildup of resistance, but the necessary rate of acquired resistance is extremely low (0.1% >>0) • Moderate fitness cost of resistance can also markedly reduce rate of increase, even of acquired resistance • Doubling times range from years to centuries • Similar to predictions for HSV-2 (Blower et al.)

  14. Conclusions • Emergence rate a key determinant of outcome • Small, hard to measure • Risk of resistance relatively low vs. other bug-drug combinations • FDA advisory group recommended against approval • Antivirals adcom vs. OTC adcom

  15. Lessons of the example • Dynamic models required to estimate population process over time • Both direct and indirect effects important • Identified surprising locus of uncertainty • Risk is only one side of the equation

  16. What the model couldn’t do • Calculate the probability of rare events (deterministic) • Account for heterogeneities of resistant strains • Be “validated” rigorously • Model predicted resistance would be low now • It is • So? • These problems not unique to dynamical approach

More Related